cmAngio®

cmAngio®: An FDA-Cleared Artificial Intelligence (AI) based detection software to identify Breast Arterial Calcifications (BAC), an incidental finding in FFDM and DBT screening mammograms. Results may be used for further patient management at the independent discretion of the interpreting physician.

BREAST ARTERIAL CALCIFICATIONS

Breast Arterial Calcifications are medial calcifications of varying attenuation and length along the walls of the arteries and are currently considered a benign incidental finding in screening mammograms. Among women who have had screening mammograms, the prevalence of BAC varies from around 12 to 42.5%. However, less than 5% of all instances of incidental findings of BAC in mammograms are reported. There is no established guideline at a state or national level for identifying, evaluating, and reporting BAC, leading to inconsistent practices across different institutions and generally low rates of reporting.

cmAngio Key Benefits

• Provides visualization of BAC location on cmAngio scorecard so radiologists can quickly see what the algorithm has identified.
• Enables BAC identification and reporting without additional radiation for the patient or procedures by the radiologist.
• Allows radiologists to incorporate relevant information into their overall patient assessment and recommendations for follow-up.
• Helps identify women who have BAC and might otherwise have gone undiagnosed until other more serious symptoms became apparent.

cmAngio Key Features

• Adjustable operating point to meet clinical goals
• Processes both FFDM and DBT exams
• Installs quickly and easily in less than an hour
• Cybersecure and HIPAA-compliant
• Compatible with any DICOM-compliant viewer
• Demonstrated performance across all breast densities

Sources

1.CSBI https://csbi.ca/canadian-society-of-breast-imaging-position-statement-on-breast-arterial-calcification-reporting-on-mammography/

2.Internal CureMetrix analysis based on data collected from 2008-2018

*Disclaimer: cmAngio® is FDA-cleared for commercial use in the U.S. FDA 510(k) Submission #K232367

CureMetrix

CureMetrix is committed to the advancement of technology that improves disease detection and survival rates worldwide. Our AI-based products and research are focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis technology that radiologists and patients can confidently rely on. Today, our powerful image analysis platform is an adjunct, precision tool for mammography. Our goal is to equip radiologists with the objective, data-driven answers they need to support patients and their healthcare team as they make decisions about their health. At CureMetrix, we believe that providing radiologists with the most advanced technology to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs, and increased assurance that patients are getting the highest standard of care available from screening.

X-Ray